West Pharmaceutical Services Stock
West Pharmaceutical Services, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Michel Lagarde
- Employees
- 10,800
- Market cap
- $27 B
- IPO
- 17/03/1980
West Pharmaceutical Services, Inc. specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company was established in 1923 and is headquartered in Exton, USA. Its operations span across the…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
West Pharmaceutical Services stock: price history
1D
+0.3%
1W
+4.9%
1M
+6.1%
6M
+40.3%
YTD
+39.6%
1Y
+43.7%
2Y
+32.9%
5Y
-5.1%
10Y
+426.3%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~216% stronger price swings than usual
West Pharmaceutical Services stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 20/08/2026.
Ask the agents about West Pharmaceutical Services
Analyst assessment of West Pharmaceutical Services
PRICE TARGET LOW
US$390.00
CONSENSUS
US$419.50
MEDIAN
US$420.00
PRICE TARGET HIGH
US$447.00
0
STRONG BUY
14
BUY
2
HOLD
1
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 13/10/2026
West Pharmaceutical Services stock metrics
P/E
48.8
P/B
9.09
EV/EBITDA
30.91
RETURN ON EQUITY
5.2%
NET MARGIN
17.7%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.2%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.3%
FLOAT SHARES
69,849,351
AVG. DAILY VOLUME (30D)
581,994
Insider transactions (SEC)
Favorite Annette F
Favorite Annette F
Favorite Annette F
Favorite Annette F
Favorite Annette F
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.3%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about West Pharmaceutical Services stock
What does West Pharmaceutical Services do?
West Pharmaceutical Services, Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Michel Lagarde, the company employs around 10,800 people.
The IPO was on 17/03/1980; the stock trades on NYSE under the ticker WST.
What do analysts say about West Pharmaceutical Services stock?
17 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$419.50, ranging from US$390.00 to US$447.00, with a median of US$420.00.
This is an external assessment, not a statement by Market Jury.
When does West Pharmaceutical Services report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 216% stronger than usual.
Does West Pharmaceutical Services pay a dividend?
Yes. The last dividend was US$0.22 per share, ex-date 29/07/2026, paid on 05/08/2026.
The dividend yield is 0.2% (as of 30/06/2026).
Which stocks are comparable to West Pharmaceutical Services?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, Solventum, Baxter International, Cooper Companies, Avantor and Repligen.
How can I get West Pharmaceutical Services stock analyzed?
Clicking "Analyze stock" lets five strategies assess West Pharmaceutical Services against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.